Dihexa
N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
An oral angiotensin IV analog that acts through the hepatocyte growth factor (HGF/MET) pathway. In lab and rat studies (2013–2014) it promoted new synapse formation, and the original report described it as about seven orders of magnitude more potent than BDNF in that cell assay. It has not been tested in human trials and is not FDA-approved.
Half-life
~hours
Typical Dose
10–20 mg/day (oral)
12/20Route
oral
Category
neuroprotective
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How Dihexa is dosed in practice
Usually taken by mouth. Typical range: 10–20 mg/day (oral). Half-life: ~hours. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Preclinical data shows remarkable cognitive enhancement in animal models of dementia and Alzheimer's disease. HGF/MET pathway activation promotes new synapse formation. No human clinical trials conducted. Extreme caution advised due to limited safety data and potent biological activity.
- McCoy et al., 2013 — Journal of Pharmacology and Experimental Therapeutics
- Benoist et al., 2014 — hippocampal spine density studies
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for Dihexa and 90+ other compounds with Pro.
Upgrade to ProInteraction Network
Known interactions with other compounds. Click nodes to explore connections.
Safety & Contraindications
- Very limited safety data — extreme caution required
- Cancer history (HGF pathway may promote tumor growth)
- Pregnancy or breastfeeding
- Liver or kidney disease
Dihexa: common questions
What is Dihexa?
An oral angiotensin IV analog that acts through the hepatocyte growth factor (HGF/MET) pathway. In lab and rat studies (2013–2014) it promoted new synapse formation, and the original report described it as about seven orders of magnitude more potent than BDNF in that cell assay. It has not been tested in human trials and is not FDA-approved.
How is Dihexa dosed?
Dihexa is usually taken by mouth. Typical range in DoseCraft's library: 10–20 mg/day (oral). Experimental (early or animal data): 10–20 mg daily (oral); Once daily; 2–4 weeks maximum (experimental). These ranges describe what has been studied or used; they are not a prescription.
Is Dihexa FDA-approved?
No. Dihexa is not approved by the FDA for any use in people.
What is the half-life of Dihexa?
DoseCraft's library lists a half-life of ~hours. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use Dihexa?
Listed contraindications: Very limited safety data — extreme caution required; Cancer history (HGF pathway may promote tumor growth); Pregnancy or breastfeeding; Liver or kidney disease.
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.